About Probable maltase-glucoamylase 2
Probable maltase-glucoamylase 2 (MGAM2) is a protein
from Homo sapiens identified by UniProt accession
Q2M2H8, 2515 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Probable maltase-glucoamylase 2 |
|---|
| UniProt accession | Q2M2H8 |
|---|
| Gene | MGAM2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2515 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (45)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.57
- diabetes mellitus · score 0.37
- abnormal glucose tolerance · score 0.37
- 1,5 anhydroglucitol measurement · score 0.34
- PHF-tau measurement · score 0.31
- blood metabolite measurement · score 0.15
- Aganglionic megacolon · score 0.11
- Hirschsprung disease · score 0.11
- chronic hepatitis C virus infection · score 0.11
- HIV infection · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q2M2H8-F1 | alphafold | PREDICTED | 74.76 | — |
Amino-acid sequence (2515 residues)
MARKLSVLEV LLIIFCLIVV TIDILLLLLV LEETSDTSFT PECPEIPQSE RIDCTPDQEV TEDICRWQYK CCWSPVADAN VPRCFFPWNW GYEASNGHTN TSTGFTAQLK RLPSPSLFGN DVATTLFTAE YQTSNRFHFK ITDFNNIRYE VSHENINLVD GIADASNLSY YVEVTDKPFS IKIMRTSNRR VLLDTSIGPL QFAQQYLQLS FRLPSANVYG LGEHVHQQYR HNMTWKTWPI FTRDATPTEG MINLYGAHTF FLCLEDARGS SFGVFLMNSN AMEVTLQPAP AITYRTIGGI LDFYVFLGNT PEQVVQEYLE LVGRPFFPPY WSLGFQLSRR DYGGINKLKE VVSRNRLAEI PYDVQYSDID YMDGKKDFTV DEVAYSGLPD FVKELHDNGQ KYLIIMNPGI SKNSNYEPYN NGSLKRVWIL GSNGFAVGEG YPGPTVFPDY TNPVCTEWWT DQVAKFHDHL EFDGVWIEMN EVSSLLQASN NQCESNNLNF PPFLPRVLDH LLFARTLCMD TEFHGGLHYD IHSLYGHSMA RTTNLALETI FMNNRSFILS RSTFAGSGKF AAHWLGDNAA TWDDLRWSIP TILEFNLFGI PMVGANICGY NNNVTEELCR RWMQLGAFYP LPRNHNGPGF RDQDPAAFGV DSLLLKSSRH YLNIRYTLLP YLYTLFYHAH TRGETVARPL VHEFYQDSAT WDVHEQFLWG PGLLITPVLY EGVDEVKAYI PDATWYDYET GVAISWRKQL VNMLLPGDKI GLHLRGGYIF PTQKPNTTTE ASRRNSLGLI IALDYKREAK GELYWDDGVS KDAVTEKKYI LYDFSVTSNH LQAKIINNNY MDTDNLMFTD ITILGMDKQP ANFIVLLNNV ATSSPSVVYN ASTKVVTITD LQGLVLGQEF SIRWNLPVSD LEKFNCYPDD PTASEESCRQ RGCLWEDTST PGVPTCYYDT IPNYVASDIQ YLNTSITADL SLPMAPESAA AAASDSLSAK ISFLHLKVIY HTATMLQVKI YDPTNKRYEV PVPLNTPPQP VGDPENRLYD VRIQNNPFGI QIQRKNSSTV IWDSQLPGFI FNDMFLSIST RLPSQYIYGF GETEHTTFRR NMNWNTWGMF AHDEPPAYKK NSYGVHPYYM ALEEDGSAHG VLLLNSNAMD VTLQPTPALT YRTTGGILDF YIVLGPTPEL VTQQYTELIG RPAMIPYWAL GFHLSRYGYQ NDAEISSLYD AMVAAQIPYD VQHVDIDYMN RKLDFTLSAN FQNLSLLIEQ MKKNGMRFIL ILDPAISGNE TQYLPFIRGQ ENNVFIKWPD TNDIVWGKVW PDLPNVIVDG SLDHETQVKL YRAYVAFPDF FRNSTAAWWK KEIEELYANP REPEKSLKFD GLWIDMNEPS NFVDGSVRGC SNEMLNNPPY MPYLESRDKG LSSKTLCMES QQILPDSSPV EHYNVHNLYG WSQTRPTYEA VQEVTGQRGV IITRSTFPSS GRWGGHRLGN NTAAWDQLGK SIIGMMEFSL FGIPYTGADI CGFFGDAEYE MCVRWMQLGA FYPFSRNHNN IGTRRQDPVA WNSTFEMLSR KVLETRYTLL PYLYTLMHKA HVEGSTVVRP LLHEFTDDRT TWDIDRQFML GPAILISPVL ETSTFEISAY FPRARWYDYS TGTSSTSTGQ RKILKAPLDH INLHVRGGYI LPWQEPAMNT HSSRQNFMGL IVALDDNGTA EGQVFWDDGQ SIDTYENGNY FLANFIAAQN ILQIQTIHNK YLSDSNPLKV GYIRIWGVNT YVTQVSFTYD NRQFMETNFK SEPYNQILTI QLTDKTINLE KLTEVTWIDG GPVLPTPTKT STIPMSSHPS PSTTNATSSE TITSSASANT TTGTTDTVPI TTTSFPSTTS VTTNTTVPDT TSPFPTSTTN ASTNATVPIT TTPFPTSTIG VTTNATVPNT TAPFPTNAST ASTNATVPIT TTCFATSTIG VTTNATVPDT TAPFPTNTTT ASTNATIPIT TTPFATSTIS VTTSTTVPDT TAPFPTSTTS ASTNATPVPI TTTLFATSTI GVTTGTTVPD TTAPFPTSTT STSTSATVPI TTTPSPTNTA DANTSNTVPN TTMPSPTSST TVSTIATVPI SVTPSLTSTA DATISTTVLI ATTSSLTGTT DVSTSTTINN ISTPVQTNTT NASTSTNVAN ITATSHTSTD DTVPNNTVPV TAIPSLANTG VDTTSNSFSI MTTSFSESTN AMNTTVIMAT TSPTSTDVAS TNNDASMTNF LLATMSAGNI TSNSISITTT SFGNSVPFVT TPSPSTDATT TSNNTNPGMT TYYQTSPTIP THTLTSIPSS ITSILSMFPT SNTFTTDKIT NFTTPTNANT IIFNTLDTKS TMVIDATVTT TSTKDNTMSP DTTVTSIDKF TTHITQFATP HSATTTTLAL SHTSLAPTNL SNLGTMDITD ADNSSSVTGN TTHISVSNLT TASVTITATG LDSQTPHMVI NSVATYLPIT ATSATTDTTN ITKYALNTTT PDSTVHTSAT APTYIANAIN ATQVP
Explore Probable maltase-glucoamylase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets